Copertina

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jia‐Ling Wu, Ying‐Nan Tsai, Cheng‐Hao Tseng, Shang‐Chen Tseng, Chih‐Wen Lin, Chih‐Lung Hung, Mindie H. Nguyen, Jaw‐Town Lin, Yao‐Chun Hsu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2026)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?
di: Yao‐Chun Hsu, et al.
Pubblicazione: (2026)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks
di: Chun‐Chieh Chen, et al.
Pubblicazione: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
di: Rui Huang, et al.
Pubblicazione: (2025)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences
di: Bi‐Yu Gao, et al.
Pubblicazione: (2025)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2026)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
di: Daniel Q. Huang, et al.
Pubblicazione: (2026)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Clearance of Hepatitis C Viremia During Direct‐Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism
di: Zahra Sarrafan‐Chaharsoughi, et al.
Pubblicazione: (2025)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
di: Tyng‐Yuan Jang, et al.
Pubblicazione: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar?
di: Danny Con
Pubblicazione: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
di: Chia‐Chih Kuo, et al.
Pubblicazione: (2025)

Late Diagnosis of Chronic Hepatitis B in the United States: A Population‐Based, Retrospective Cohort Study From 2007 to 2021
di: Michael H. Le, et al.
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
di: Lesley A. Patmore, et al.
Pubblicazione: (2025)

Correction to ‘Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon’
Pubblicazione: (2025)

Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort
di: Najib Ben Khaled, et al.
Pubblicazione: (2025)

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure
di: Yanxue Lin, et al.
Pubblicazione: (2025)

Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
di: Soon Sun Kim, et al.
Pubblicazione: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
di: Yi‐Ping Hung, et al.
Pubblicazione: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
di: Linda Henry, et al.
Pubblicazione: (2024)

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
di: Vincent Haghnejad, et al.
Pubblicazione: (2025)

Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
di: Jialing Wang, et al.
Pubblicazione: (2025)

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma
di: Rong Ding, et al.
Pubblicazione: (2026)

PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study
di: Daniel Q. Huang, et al.
Pubblicazione: (2026)

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
di: Chia‐Chih Kuo, et al.
Pubblicazione: (2025)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
di: Kanghee Park, et al.
Pubblicazione: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
di: Eunice Yewon Lee, et al.
Pubblicazione: (2024)

Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL‐B Study
di: Rui Huang, et al.
Pubblicazione: (2025)

Genetic Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance and Its Associated Viral Markers
di: Jun Tao, et al.
Pubblicazione: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
di: Zhejin Shi, et al.
Pubblicazione: (2026)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
di: Darren Jun Hao Tan, et al.
Pubblicazione: (2024)

Very Early‐Stage Detection Is Associated With Improved Survival in Patients With Unifocal Hepatocellular Carcinoma
di: Thomas Hunold, et al.
Pubblicazione: (2025)